Val D'Hebron Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garralda, Elena
SERPENTINE, NCT06680739: Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting
2
60
Europe
Durvalumab, Tremelimumab
Vall d'Hebron Institute of Oncology
Colorectal Cancer, Endometrial Cancer
09/25
12/25
PragmaTIL, NCT06630611: Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer

Recruiting
2
40
Europe
NMA-LD regimen, Cyclophosphamide and Fludarabine, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2, IL-2 analog
Vall d'Hebron Institute of Oncology, Banc de Sang i Teixits
Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
09/29
09/29
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers

Completed
1/2
85
Europe, US, RoW
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Affimed GmbH
Advanced Solid Tumor
07/23
06/24
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Withdrawn
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
EVICTION, NCT04243499 / 2019-003847-31: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Checkmark Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Sep 2022 - Sep 2022: Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Recruiting
1/2
150
Europe, US
IV ICT01
ImCheck Therapeutics, ImCheck Therapeutics, Inc.
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
06/25
12/25
GCT1055-01, NCT06391775: Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Recruiting
1/2
270
Europe, US
GEN1055, Pembrolizumab, Standard Chemotherapy
Genmab, BioNTech SE
Malignant Solid Tumor
05/28
05/28
IMAG1NE, NCT05430555: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors

Terminated
1/2
23
Europe
Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
T-knife GmbH
Advanced Solid Tumors
01/24
01/24
MYCure, NCT04808362 / 2020-003802-30: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

Terminated
1/2
22
Europe
OMO-103
Peptomyc S.L., Peptomyc S.L.
Advanced Solid Tumors, Pancreatic Cancer, CRC
12/22
01/23
NCT05435339 / 2021-006692-42: A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Terminated
1/2
31
Europe, US
GEN1053
Genmab, BioNTech SE
Solid Tumor, Adult
05/24
05/24
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26
GDFATHER, NCT04725474 / 2020-002103-19: First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer

Active, not recruiting
1/2
274
Europe
visugromab (CTL-002)
CatalYm GmbH, CatalYm GmbH
Solid Tumor, Adult
10/25
10/27
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
225
Europe, US
TNG462, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28
NCT05076396: PM14 Administered Intravenously to Patients with Advanced Solid Tumors

Recruiting
1
150
Europe, US
PM14
PharmaMar
Advanced Solid Tumor
08/25
08/25
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
TT-CSP-001, NCT06403436: A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Recruiting
1
50
Europe
TT125-802
TOLREMO therapeutics AG
Advanced Solid Tumor, Adult Solid Tumor, Adult Disease, Cancer, NSCLC
07/25
12/25
VICTORIA-01, NCT06163391: A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Recruiting
1
40
Europe, US, RoW
SOT201
SOTIO Biotech AG
Advanced Solid Tumor, Metastatic Solid Tumor
10/26
10/26
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
NCT05385705: A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Recruiting
1
20
Europe
Cyclophosphamide, Trastuzumab, Pertuzumab, NK cells, Interleukin-2
Vall d'Hebron Institute of Oncology, Clinica Universidad de Navarra, Universidad de Navarra, Puerta de Hierro University Hospital, Hospital del Mar, Banc de Sang i Teixits
Breast Neoplasms
09/26
04/27
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT06458712: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants with Advanced Malignancies

Recruiting
1
90
Europe
DSB2455
Duke Street Bio Ltd
Advanced Malignancies with Homologous Recombination Deficiency (HRD) (Breast, Ovarian, MCRPC, Brain Metastases)
08/27
08/28
RP2-001-18, NCT04336241: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Hourglass Oct 2021 - Dec 2021 : Updated data from trial in combination with RP2 for solid tumors
Checkmark From trial in combination with RP2 for solid tumors at ASCO 2021
Jun 2021 - Jun 2021: From trial in combination with RP2 for solid tumors at ASCO 2021
Recruiting
1
36
Europe
RP2, nivolumab, Opdivo
Replimune Inc.
Cancer
10/26
04/28
NEXTGENTIL-ACT, NCT05141474: Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Recruiting
1
10
Europe
NEXTGEN-TIL, Tumor-infiltrating Lymphocyte Adoptive Cell Therapy, Non-myeloablative Lymphodepletion (NMA-LD) Regimen, Cyclophosphamide, Fludarabine, Interleukin-2, IL-2, Aldesleukin
Vall d'Hebron Institute of Oncology, Banc de Sang i Teixits
Epithelial Tumors, Malignant, Malignant Solid Tumor
01/27
01/27
Matos, Ignacio
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
Pedrazzoli, Analia Azaro
No trials found

Download Options